163 filings
8-K
EPIX
Essa Pharma Inc
14 May 24
Results of Operations and Financial Condition
7:01am
8-K
EPIX
Essa Pharma Inc
7 Mar 24
Submission of Matters to a Vote of Security Holders
5:18pm
8-K
EPIX
Essa Pharma Inc
13 Feb 24
Results of Operations and Financial Condition
7:01am
8-K
EPIX
Essa Pharma Inc
29 Jan 24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
9:15am
8-K
EPIX
Essa Pharma Inc
12 Dec 23
Results of Operations and Financial Condition
7:01am
8-K
c7bn gog1
6 Nov 23
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
4:57pm
8-K
264lp38 1sip3
26 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
8:07pm
8-K
q5fz 6nx1phd
23 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
4:19pm
8-K
eq5g1hiz
18 Sep 23
Updated Phase 1 results selected for a poster presentation at ESMO 2023
7:05am
8-K
k9ctxrvehvbsm7n
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
7:56pm
8-K
04slp7nni701eojyx
8 Aug 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
7:15am
8-K
2ni3daaq
6 Jun 23
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
4:15pm
8-K
iogacf
9 May 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
9:01am
8-K
1vx84ob8y
12 Apr 23
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
7:02am
8-K
ytebdldcp999gt0othi
10 Mar 23
Submission of Matters to a Vote of Security Holders
12:50pm
8-K
m0qitm65p 5hqv2dy
7 Feb 23
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
7:02am
8-K
ip6bswauq5lmgba3tb
13 Dec 22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2022 Fiscal Year
7:01am
8-K
1h4yuzir90n vy
31 Oct 22
ESSA Provides an Update on its Clinical Collaboration with Janssen
7:11am
8-K
m5en6e phql6g7
26 Oct 22
Regulation FD Disclosure
7:33am
8-K
jg1in285b
13 Sep 22
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
5:02pm